WAM
ADPT icon

Weiss Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Weiss Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-51,521
Closed -$715K – 641
2022
Q1 		$715K Buy
+51,521
New +$810K 0.01% 595

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Weiss Asset Management's ADPT Position: Q2 2022 in Review

Weiss Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 51,521 shares — an estimated $715K sold.

Weiss Asset Management first reported a position in ADPT in Q1 2022 and held it in 1 quarter. The position peaked at $715K in Q1 2022. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

  • Weiss Asset Management reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • Weiss Asset Management sold 51,521 Adaptive Biotechnologies shares in Q2 2022, an estimated $715K.
  • Weiss Asset Management first reported a position in Adaptive Biotechnologies in Q1 2022 and held it in 1 quarter.
  • Weiss Asset Management's Adaptive Biotechnologies position peaked at $715K in Q1 2022.
  • 209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Weiss Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.